Literature DB >> 18276667

The population impact on incidence of suicide and non-fatal self harm of regulatory action against the use of selective serotonin reuptake inhibitors in under 18s in the United Kingdom: ecological study.

Benedict W Wheeler1, David Gunnell, Chris Metcalfe, Peter Stephens, Richard M Martin.   

Abstract

OBJECTIVE: To investigate the population impact on the incidence of suicide and non-fatal self harm of regulatory action in 2003 to restrict the use of selective serotonin reuptake inhibitors (SSRIs) in under 18s.
DESIGN: Ecological time series study.
SETTING: United Kingdom. Populations Young people in the UK aged 12-19 years (prescribing trends), in England and Wales aged 12-17 years (mortality), and in England aged 12-17 years (hospital admissions). MAIN OUTCOME MEASURES: Deaths from suicide and hospital admissions for self harm.
RESULTS: Antidepressant prescribing doubled between 1999 and 2003 but fell to the 1999 level between 2004 and 2005. These large changes in prescribing did not seem to be associated with temporal trends in suicide or self harm. In the years 1993 to 2005 the annual percentage reduction for suicide among 12-17 year olds was -3.9% (95% confidence interval -6.2% to -1.5%) in males and -3.0% (-6.6% to 0.6%) in females, with no indication of a substantial change in this rate of decrease during that period. Similarly, hospital admission rates for self harm in the years 1999 to 2005 indicated an annual percentage increase for males of 1.1% (-0.5% to 2.7%) and for females of 5.7% (3.6% to 7.8%), again with no statistical evidence of a change in rate after the regulatory action.
CONCLUSIONS: The noticeable reduction in prescribing of antidepressants since regulatory action in 2003 to restrict the use of SSRIs in under 18s does not seem to have been associated with changes in suicidal behaviour in young people. Specifically, these data for England do not indicate that reductions in antidepressant use have led to an increase in suicidal behaviour.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18276667      PMCID: PMC2265377          DOI: 10.1136/bmj.39462.375613.BE

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  11 in total

1.  Permutation tests for joinpoint regression with applications to cancer rates.

Authors:  H J Kim; M P Fay; E J Feuer; D N Midthune
Journal:  Stat Med       Date:  2000-02-15       Impact factor: 2.373

2.  Relationship between antidepressant medication treatment and suicide in adolescents.

Authors:  Mark Olfson; David Shaffer; Steven C Marcus; Ted Greenberg
Journal:  Arch Gen Psychiatry       Date:  2003-10

Review 3.  Antidepressants and suicide: what is the balance of benefit and harm.

Authors:  David Gunnell; Deborah Ashby
Journal:  BMJ       Date:  2004-07-03

4.  Did intense adverse media publicity impact on prescribing of paroxetine and the notification of suspected adverse drug reactions? Analysis of routine databases, 2001-2004.

Authors:  Richard M Martin; Margaret May; David Gunnell
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

5.  Effects of the Committee on Safety of Medicines advice on antidepressant prescribing to children and adolescents in the UK.

Authors:  Macey L Murray; Mary Thompson; Paramala J Santosh; Ian C K Wong
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

6.  Impact of the FDA black box warning on physician antidepressant prescribing and practice patterns: opening Pandora's suicide box.

Authors:  Timothy W Lineberry; J Michael Bostwick; Timothy J Beebe; Paul A Decker
Journal:  Mayo Clin Proc       Date:  2007-04       Impact factor: 7.616

Review 7.  Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data.

Authors:  Craig J Whittington; Tim Kendall; Peter Fonagy; David Cottrell; Andrew Cotgrove; Ellen Boddington
Journal:  Lancet       Date:  2004-04-24       Impact factor: 79.321

8.  Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents.

Authors:  Robert D Gibbons; C Hendricks Brown; Kwan Hur; Sue M Marcus; Dulal K Bhaumik; Joëlle A Erkens; Ron M C Herings; J John Mann
Journal:  Am J Psychiatry       Date:  2007-09       Impact factor: 18.112

9.  Why are suicide rates rising in young men but falling in the elderly?-- a time-series analysis of trends in England and Wales 1950-1998.

Authors:  David Gunnell; Nicos Middleton; Elise Whitley; Daniel Dorling; Stephen Frankel
Journal:  Soc Sci Med       Date:  2003-08       Impact factor: 4.634

10.  Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs.

Authors:  Anne M Libby; David A Brent; Elaine H Morrato; Heather D Orton; Richard Allen; Robert J Valuck
Journal:  Am J Psychiatry       Date:  2007-06       Impact factor: 18.112

View more
  25 in total

Review 1.  Strategies for quantifying the relationship between medications and suicidal behaviour: what has been learned?

Authors:  Robert D Gibbons; J John Mann
Journal:  Drug Saf       Date:  2011-05-01       Impact factor: 5.606

Review 2.  Impact of safety-related regulatory action on clinical practice: a systematic review.

Authors:  Sigrid Piening; Flora M Haaijer-Ruskamp; Jonie T N de Vries; Menno E van der Elst; Pieter A de Graeff; Sabine M J M Straus; Peter G M Mol
Journal:  Drug Saf       Date:  2012-05-01       Impact factor: 5.606

3.  Antidepressants and suicide.

Authors:  Gregory Simon
Journal:  BMJ       Date:  2008-02-14

4.  Trends in prescribing and self-poisoning in relation to UK regulatory authority warnings against use of SSRI antidepressants in under-18-year-olds.

Authors:  Helen Bergen; Keith Hawton; Elizabeth Murphy; Jayne Cooper; Navneet Kapur; Carol Stalker; Keith Waters
Journal:  Br J Clin Pharmacol       Date:  2009-10       Impact factor: 4.335

Review 5.  Antidepressant drugs and the risk of suicide in children and adolescents.

Authors:  Göran Isacsson; Charles L Rich
Journal:  Paediatr Drugs       Date:  2014-04       Impact factor: 3.022

6.  Impact of medicines regulatory risk communications in the UK on prescribing and clinical outcomes: Systematic review, time series analysis and meta-analysis.

Authors:  Christopher J Weatherburn; Bruce Guthrie; Tobias Dreischulte; Daniel R Morales
Journal:  Br J Clin Pharmacol       Date:  2019-12-16       Impact factor: 4.335

Review 7.  Unintended Effects of Communicating About Drug Safety Issues: A Critical Review of the Literature.

Authors:  Jessica T DeFrank; Lauren McCormack; Suzanne L West; Craig Lefebvre; Olivia Burrus
Journal:  Drug Saf       Date:  2019-10       Impact factor: 5.606

8.  Decreased Use of Antidepressants in Youth After US Food and Drug Administration Black Box Warning.

Authors:  Tanvir Singh; Ashwin Prakash; Theodore Rais; Neeta Kumari
Journal:  Psychiatry (Edgmont)       Date:  2009-10

9.  Suicidal behavior and alcohol abuse.

Authors:  Maurizio Pompili; Gianluca Serafini; Marco Innamorati; Giovanni Dominici; Stefano Ferracuti; Giorgio D Kotzalidis; Giulia Serra; Paolo Girardi; Luigi Janiri; Roberto Tatarelli; Leo Sher; David Lester
Journal:  Int J Environ Res Public Health       Date:  2010-03-29       Impact factor: 3.390

10.  How do we safely treat depression in children, adolescents and young adults?

Authors:  Jon Jureidini
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.